Notwithstanding positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from pharmacy benefit managers. The https://cyrusybbf456445.loginblogin.com/50234762/the-vyndamax-faces-is-encountering-managed-care-organization-challenges-a-look-at-access-fights